Lixivaptan: a novel vasopressin receptor antagonist

Bibliography

• Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(Suppl 1):S1-21
   Google Scholar
• Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-58
   PubMed Web of Science ®Google Scholar
• Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-32
   PubMed Web of Science ®Google Scholar
• Lolait SJ, O'Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995;92:6783-7
   PubMed Web of Science ®Google Scholar
• Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549-52
   PubMed Web of Science ®Google Scholar
• Umenishi F, Narikiyo T, Vandewalle A, Schrier RW. cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta 2006;1758:1100-5
   PubMed Web of Science ®Google Scholar
• Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-64
   PubMed Web of Science ®Google Scholar
• Ghali JK. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 2008;111:147-57
   PubMed Web of Science ®Google Scholar
• Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Nephrol Dial Transplant 1996;11:1034-42
   PubMed Web of Science ®Google Scholar
• Schrier RW, Cadnapaphornchai MA, Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J R Soc Med 2001;94:265-9
   PubMed Web of Science ®Google Scholar
• Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988;319:1065-72
   PubMed Web of Science ®Google Scholar
• Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-90
   PubMed Web of Science ®Google Scholar
• Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Effect Resour Alloc 2006;4:10
   PubMedGoogle Scholar
• Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169-72
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(Suppl 1):S30-5
   PubMed Web of Science ®Google Scholar
• Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996;156:1814-20
   PubMed Web of Science ®Google Scholar
• Farmakis D, Filippatos G, Parissis J, et al. Hyponatremia in heart failure. Heart Fail Rev 2009;14:59-63
   PubMed Web of Science ®Google Scholar
• Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82-6
   PubMedGoogle Scholar
• Cardenas A, Gines P. Predicting mortality in cirrhosis – serum sodium helps. N Engl J Med 2008;359:1060-2
   PubMed Web of Science ®Google Scholar
• Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-30
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-9
   PubMed Web of Science ®Google Scholar
• Gross P. Treatment of hyponatremia. Intern Med 2008;47:885-91
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31
   PubMed Web of Science ®Google Scholar
• Albright JD, Reich MF, Delos Santos EG, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo [2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;41:2442-4
   PubMed Web of Science ®Google Scholar
• Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998;449:439-43
   PubMed Web of Science ®Google Scholar
• Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410-21
   PubMed Web of Science ®Google Scholar
• Martinez-Castelao A. Lixivaptan (American Home Products). Curr Opin Investig Drugs 2001;2:525-30
   PubMedGoogle Scholar
• Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36:1197-205
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-91
   PubMed Web of Science ®Google Scholar
• Kumar S, Rubin S, Mather PJ, Whellan DJ. Hyponatremia and vasopressin antagonism in congestive heart failure. Clin Cardiol 2007;30:546-51
   PubMed Web of Science ®Google Scholar
• Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-21
   PubMed Web of Science ®Google Scholar
• Biogen Idek and Cardiokine Partner to Develop Lixivaptan, a Novel Vasopressin Antagonist. 2007. Available from: http://www.reuters.com/article/pressRelease/idUS162428+14-Feb-2008+BW20080214 [last accessed 6 April 2009]
   Google Scholar
• Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138:18-21
   PubMed Web of Science ®Google Scholar
• Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-8
   PubMed Web of Science ®Google Scholar
• Gattone VH 2nd. Emerging therapies for polycystic kidney disease. Curr Opin Pharmacol 2005;5:535-42
   PubMed Web of Science ®Google Scholar
• Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004;66:964-73
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460-71
   PubMed Web of Science ®Google Scholar
• Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 2008;28:306-17
   PubMed Web of Science ®Google Scholar
• Shimizu K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int 1995;48:220-6
   PubMed Web of Science ®Google Scholar
• Steiner M, Phillips MI. Renal tubular vasopressin receptors downregulated by dehydration. Am J Physiol 1988;254:C404-10
   PubMed Web of Science ®Google Scholar